Tesamorelin vs Sermorelin

Overview

This comparison separates Tesamorelin and Sermorelin for reference—not product selection.

Tesamorelin: GHRH analogue approved for HIV-associated excess abdominal fat; studied for visceral fat specifically.

Sermorelin: GHRH analogue formerly approved for diagnosing growth hormone deficiency, withdrawn commercially.

Differences

• Both appear in Growth hormone & endocrine research literature, but mechanistic framing differs.
• The useful distinction is research question and receptor context—not relative potency or practical ranking.

Mechanism

Tesamorelin: Tesamorelin acts on the GHRH receptor in the pituitary gland, prompting release of the body's own growth hormone in its normal pulsed pattern rather than supply…

Sermorelin: Subcutaneous injection provides optimal bioavailability for binding GHRH receptors, stimulating pulsatile GH release while maintaining hypothalamic-pituitary ax…

Pharmacology

Tesamorelin: Pharmacokinetic detail should be read from primary literature.

Sermorelin: Pharmacokinetic detail should be read from primary literature.

Research

Tesamorelin: Growth hormone & endocrine research: FDA-approved indication showing 15-20% visceral fat reduction in clinical trials.

Sermorelin: Growth hormone & endocrine research: 1.26kg lean mass increase documented in elderly men with improved muscle strength tests.

Summary

Distinction

• AXIOM does not provide dosing, administration, or protocol guidance.
• Catalogue links appear only where AXIOM lists a research-use product.
• Reference-only compounds remain comparison terms without implying availability.

References

• pubmed.ncbi.nlm.nih.gov/18057338/
• pubmed.ncbi.nlm.nih.gov/22869065/
• pubmed.ncbi.nlm.nih.gov/20101189/
• pubmed.ncbi.nlm.nih.gov/31611038/
• pubmed.ncbi.nlm.nih.gov/41545261/
• pubmed.ncbi.nlm.nih.gov/2877535/
• pubmed.ncbi.nlm.nih.gov/8772599/
• pubmed.ncbi.nlm.nih.gov/9141536/

Questions